AC
TAK icon

Adelphi Capital’s Takeda Pharmaceutical TAK Stock Holding History

Adelphi Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,584,930
Closed -$138M – 3
2020
Q4 		$138M Sell
7,584,930
-689,297
-8% -$12.1M 26.79% 2
2020
Q3 		$148M Sell
8,274,227
-882,088
-10% -$16.1M 28.67% 2
2020
Q2 		$164M Sell
9,156,315
-126,228
-1% -$2.27M 36.01% 2
2020
Q1 		$141M Buy
9,282,543
+323,759
+4% +$5.87M 33.82% 2
2019
Q4 		$177M Sell
8,958,784
-32,506
-0.4% -$622K 33.75% 2
2019
Q3 		$155M Buy
8,991,290
+1,060,174
+13% +$18.3M 33.43% 2
2019
Q2 		$140M Sell
7,931,116
-1,339,419
-14% -$24.4M 32.92% 2
2019
Q1 		$189M Buy
+9,270,535
New +$187M 39.13% 2

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Adelphi Capital's TAK Position: Q1 2021 in Review

Adelphi Capital sold out of Takeda Pharmaceutical (TAK) in Q1 2021, closing a stake of 7,584,930 shares — an estimated $138M sold.

Adelphi Capital first reported a position in TAK in Q1 2019 and held it in 8 quarters. The position peaked at $189M in Q1 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q1 2021.

  • Adelphi Capital reported no remaining Takeda Pharmaceutical position as of Q1 2021 after selling out during the quarter.
  • Adelphi Capital sold 7,584,930 Takeda Pharmaceutical shares in Q1 2021, an estimated $138M.
  • Adelphi Capital first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 8 quarters.
  • Adelphi Capital's Takeda Pharmaceutical position peaked at $189M in Q1 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2021.

Based on Adelphi Capital's 13F filing for Q1 2021, filed 22 Apr 2021.